The trial’s primary endpoint is the change in gout pain intensity from baseline in the target joint at day three.

Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be ...

Q1 2025 Earnings Call Transcript May 9, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.7, expectations were $1.37. Operator: Please stand by. Your program is about to ...

ANI Pharma initiates phase 4 trial of purified Cortrophin Gel to treat acute gout flares: Princeton, New Jersey Friday, May 23, 2025, 14:00 Hrs [IST] ANI Pharmaceuticals, Inc., a ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a pharmaceutical company with a market capitalization of $1.15 billion and impressive revenue growth of 30% over the last twelve months, announced ...

These are not all the adverse reactions reported with Cortrophin Gel. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, ...

ANI Pharmaceuticals (NASDAQ:ANIP) is gearing up to announce its quarterly earnings on Friday, 2025-05-09. Here's a quick overview of what investors should know before the release. Analysts are ...

ANI Pharmaceuticals has reported a strong first quarter for 2025, with earnings per share (EPS) of $1.70, significantly surpassing the forecasted EPS of $1.34. The company’s revenue reached $197 ...